Eastern Cooperative Oncology Group

描述(申请人提供)：梅奥诊所是东方合作肿瘤学小组的成员已有30年之久。这项赠款申请的目的是支持梅奥诊所继续成为东部合作肿瘤学小组的成员。这些目标是为了更好地了解恶性肿瘤，更好地了解恶性疾病中的相关问题，开发改进的恶性疾病治疗计划，并提高恶性疾病患者的存活率。梅奥诊所拥有资源、人员、设施和患者群体，为ECOG的研究计划做出了强有力的贡献。随着梅奥医疗实践的不断增长和发展，我们预计会有重大的议定书条目和科学贡献。ECOG与其强大的治疗和辅助实验室计划相结合，为梅奥诊所、其研究人员、其附属的地区性癌症计划以及参与这些研究活动的一大批恶性疾病患者提供了重大好处。这项赠款建议的具体目的是支持梅奥诊所经社理事会研究活动的以下几个方面：1.评估新的方案设计和治疗方案，为全组提供针对恶性疾病的ECOG第二阶段和第三阶段治疗方案；协调和参与与ECOG恶性疾病治疗方案相关的基于实验室的辅助相关研究；恶性血液病新的预后因素和指标的发展；参与针对疾病的应计费用和活动；5)以及参加经社理事会的行政活动。这些目标将被纳入临床试验基础设施，专注于机构患者护理质量、临床研究助理(CRA)发展和教师发展。

DESCRIPTION (provided by applicant): The Mayo Clinic has been a member of the Eastern Cooperative Oncology Group for 30 years. The purpose of this grant application is to support the continued membership of the Mayo Clinic in the Eastern Cooperative Oncology Group. The goals are directed toward a greater understanding of malignancies, a better understanding of related problems in malignant diseases, development of improved treatment programs in malignant diseases, and improved patient survival in malignant diseases. Mayo Clinic has the resources, personnel, facilities, and patient population to facilitate strong contributions to the research programs of ECOG. With the continued growth and development of the Mayo medical practice, we would anticipate significant protocol entry and scientific contributions. The ECOG affiliation with its strong treatment and ancillary laboratory programs which have evolved provide major benefits to Mayo Clinic, its investigators, its affiliated regional cancer programs, and the large group of patients with malignant diseases who are involved in these research activities. The specific aims of this grant proposal are to support the following aspects of Mayo Clinic ECOG research activities which include the following: 1.) evaluation of new protocol design and treatment regimens to provide group-wide ECOG Phase II and Phase III treatment protocols in malignant diseases; 2.) coordination of, and participation in, adjunctive laboratory-based correlative studies in association with ECOG treatment protocols in malignant diseases; 3.) development of new prognostic factors and indexes in hematologic malignancies; 4.) participation in disease-specific accrual and activities; 5.) and participation in administrative activities in ECOG. These aims will be incorporated into a clinical trial infrastructure that is focused on institutional patient quality of care, clinical research associate (CRA) development, and faculty development.